Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors

Overview of attention for article published in Frontiers in oncology, December 2020

Altmetric Badge

Mentioned by

So far, Altmetric has seen 7 X posts from 1 X users, with an upper bound of 792 followers.

Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional ... https://t.co/WlrNAUEhJL

Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional ... https://t.co/WlrNAUEhJL

Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional ... https://t.co/WlrNAUEhJL

Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional ... https://t.co/WlrNAUEhJL

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 3 additional X posts.